Key result
CYP2C19-guided tigretol cuts total major cardiovascular events ~44% vs clopidogrel in older ACS patients.
Why the study?
It was unclear whether cyp2c19 gene testing provides clinical benefit for patients aged 60 years and older with acute coronary syndrome.
Does CYP2C19 gene-guided selection of ticagrelor improve prognosis compared to clopidogrel in patients aged 60 years and older with acute coronary syndrome?
Meta-Analysis (n=1,647)
Does CYP2C19 gene-guided selection of ticagrelor improve prognosis compared to clopidogrel in patients aged 60 years and older with acute coronary syndrome?
Answers are grounded in this paper and cite their sources.
In older patients with ACS, CYP2C19 gene-guided use of ticagrelor may offer better clinical benefit than clopidogrel, though with increased bleeding risk.
Objective Whether cyp2c19 gene testing is clinically beneficial for patients aged 60 years and older with acute coronary syndrome. Methods A computerized search of WIFANG, CNKI, CBM and Vipul databases was performed to comprehensively collect RCTs on cyp2c19 gene-guided selection of different antiplatelet regimens or placebo or blank control comparisons. Results A total of 8 RCTs were included. cyp2c19 gene-guided prognosis regarding antiplatelet regimens in the elderly was better in the tigretol group than in the clopidogrel group, with statistically significant differences. CONCLUSION: Current evidence suggests that in the context of acute coronary syndromes in patients, with reference to the cyp2c19 gene and age, the overall clinical benefit of tigretol may be much better than clopidogrel, although patients may be at greater risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Binbin Zhen (2023) conducted a meta-analysis in Acute coronary syndrome (n=1,647). Tigretol vs. Clopidogrel was evaluated on Total MACE incidence (RR 0.56, 95% CI 0.33-0.95, p=0.03). In patients aged 60 years and older with acute coronary syndrome, cyp2c19 gene-guided antiplatelet therapy with tigretol reduced total major cardiovascular events compared to clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: